IP Library Granted Patent US 8,435,576
Granted Patent B2
US 8,435,576 · App. 11/883,265 · Granted May 7, 2013

Use of cocoa polyphenols for treating a prostate hyperplasia, a specific cocoa extract and applications

Inventors: Philippe Troplin (Louviers, FR); Herwig Bernaert (Merelbeke, BE)
Assignee: Barry Callebaut AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,576
App. No.
11/883,265
Granted
May 7, 2013
Kind
B2
Abstract

The invention relates to the use of cacao polyphenols for preventing or curing a prostate hyperplasia, to a cacao polyphenol extract which also comprises, in particular lipids and/or xanthines, and to the applications of said extract in food and pharmaceutical products for treating a prostate cancer, cognitive disorders, oxidative stress and cholesterol.

Claims (9)

1. A method for treating prostate hyperplasia comprising administering a patient in need thereof a medicament comprising a cocoa polyphenol extract, wherein the cocoa polyphenol extract comprises:

20% to 50% by mass of polyphenols, wherein the polyphenols comprises 55% to 80% by mass flavonoids,

3% to 15% by mass of lipids, wherein the lipids comprise 1% to 15% by mass β-sitosterol, and

5% to 20% by mass of xanthines.

2. The method of claim 1 , characterized in that the treatment relates to a benign hyperplasia of the prostate.

3. The method of claim 1 , characterized in that the treatment relates to a prostate hyperplasia resulting from a prostate cancer.

4. The method of claim 1 , characterized in that the medicament is administered orally, intravenously or via subcutaneous injection.

5. The method of claim 1 , characterized in that the medicament is administered at a dose of from 15 to 30 mg/kg/day orally.

6. The method of claim 1 , characterized in that the medicament is administered at a dose of from 40 to 60 mg/kg/day orally.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 21, 2023
From: BARRY CALLEBAUT AG
To: BARRY CALLEBAUT AG
Reel/Frame 063635/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2008
From: TROPLIN, PHILIPPE; BERNAERT, HERWIG
To: BARRY CALLEBAUT AG
Reel/Frame 020875/0703 →
Continuity (3)
Provisional Application 60647404 · Jan 28, 2005
Provisional Application 60739930 · Nov 28, 2005
Related Publication 20090023803A1 · Jan 22, 2009